Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer

SIMPLE SUMMARY: NSCLC accounts for approximately 84% of lung malignancies and the clinical application of ICIs provides a novel and promising strategy. However, approximately 80% of NSCLC patients do not benefit from ICIs due to drug resistance complicated by disciplines and diverse mechanisms. Thro...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Qinying, Wei, Xiangzhen, Wang, Zhonglin, Zhu, Yan, Zhao, Weiying, Dong, Yuchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316464/
https://www.ncbi.nlm.nih.gov/pubmed/35884355
http://dx.doi.org/10.3390/cancers14143294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316464/
https://www.ncbi.nlm.nih.gov/pubmed/35884355
http://dx.doi.org/10.3390/cancers14143294

Ejemplares similares